Fiche société
Alexion Pharmaceuticals, Inc.
Traitements, essais et publications liés.
Traitements13programmes
Essais9liés
Publications9liées
SourceDBlocale
Traitements
13| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ALXN1720The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR). | Myasthénie | Phase 3 | À vérifier | United States, Argentina, Austria, Brazil, Canada, China, Denmark, France, … | À vérifier |
| GefurulimabThe primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study. | Myasthénie | Phase 3 | À vérifier | United States, Brazil, Japan, Poland, Taiwan | À vérifier |
| Oral Corticosteroid Tapering ScheduleThis is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab. | Myasthénie | Phase 4 | À vérifier | United States, Germany, Italy, Japan | À vérifier |
| RavulizumabThe Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab. | Maladie rénale chronique, Myasthénie | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, France, Germany, … | À vérifier |
| UltomirisThe primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk. | Myasthénie | À vérifier | À vérifier | United States, Australia, France, Germany, Italy, South Korea, United Kingdom | À vérifier |
| RavulizumabThe Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab. | Myasthénie | À vérifier | À vérifier | Poland | À vérifier |
| Oral Corticosteroid Tapering ScheduleThis is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab. | Myasthénie | Phase 4 | À vérifier | United States, Germany, Italy, Japan | À vérifier |
| RavulizumabThe Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab. | Myasthénie | Phase 3 | À vérifier | China | À vérifier |
| ALXN1720The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR). | Myasthénie | Phase 3 | À vérifier | United States, Argentina, Austria, Brazil, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Portugal, Serbia, South Korea, Spain, Switzerland, Taiwan, … | À vérifier |
| RavulizumabThe Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab. | Myasthénie | Phase 3 | À vérifier | United States, Italy, Japan, Serbia, Switzerland | À vérifier |
| UltomirisThe primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk. | Myasthénie | À vérifier | À vérifier | United States, Australia, France, Germany, Italy, South Korea, United Kingdom | À vérifier |
| GefurulimabThe primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study. | Myasthénie | Phase 3 | À vérifier | United States, Brazil, Japan, Poland, Taiwan | À vérifier |
| RavulizumabThe Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab. | Maladie rénale chronique | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, France, Germany, Hong Kong, India, Israel, Italy, Japan, Netherlands, Poland, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom | À vérifier |
Essais cliniques
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ravulizumab | Maladie rénale chronique | Phase 3 | NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | TERMINATED |
| Gefurulimab | Myasthénie | Phase 3 | NCT06607627 | PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | RECRUITING |
| Ultomiris | Myasthénie | À vérifier | NCT06312644 | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy | RECRUITING |
| Ravulizumab | Myasthénie | Phase 3 | NCT05644561 | Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| ALXN1720 | Myasthénie | Phase 3 | NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Ravulizumab | Myasthénie | Phase 3 | NCT07596784 | Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | RECRUITING |
| Oral Corticosteroid Tapering Schedule | Myasthénie | Phase 4 | NCT07221838 | OCTAGON — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | RECRUITING |
| eculizumab | Myasthénie | Phase 2 | NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | TERMINATED |
| Ravulizumab | Myasthénie | À vérifier | NCT06909253 | MG-ARCADIA — Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis | RECRUITING |
Publications
9| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Ultomiris | Ravulizumab: A Review in Generalised Myasthenia Gravis. | Drugs | ||
| Ravulizumab | Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making. | Journal of medical economics | ||
| Ravulizumab | Influenza A(H1N1) triggered atypical hemolytic uremic syndrome in a child with homozygous CD46 variant successfully treated with ravulizumab: a case report. | CEN case reports | ||
| Ravulizumab | Sustained terminal complement inhibition on the endothelium with ravulizumab in patients with atypical Haemolytic Uremic Syndrome. | Nephron | ||
| Ravulizumab | Clinical similarity in cost-comparison evaluations: a systematic review of current methods in NICE appraisals and the development of a framework for the formal assessment of clinical similarity. | BMJ open | ||
| Ravulizumab | A decade of complement inhibition in post-transplant atypical HUS: outcomes with eculizumab and ravulizumab. | Clinical kidney journal | ||
| Ravulizumab | Comparative Evaluation of Rituximab Versus Approved Therapies in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Network Meta-analysis. | Neurology and therapy | ||
| Ravulizumab | Clinical course of critical demyelinating lesion-associated progressive multiple sclerosis. | Journal of neurology | ||
| Ravulizumab | Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results. | Neurology(R) neuroimmunology & neuroinflammation |